US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Kelyniam Global, Inc.

0.1398

0.0000

Volume:- -

Turnover:- -

Market Cap:7.07M

PE:-19.00

High:0.1398

Open:0.1398

Low:0.1398

Close:0.1398

52wk High:0.3399

52wk Low:0.0530

Shares:50.54M

Float Shares:49.41M

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.0074

EPS(LYR):-0.0074

ROE:-31.64%

ROA:-9.25%

PB:11.40

PE(LYR):-19.00

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Kelyniam Global Q3 revenue falls 12% to $2.19 million

Press Release: Kelyniam Global Announces Q3 2025 Financial Results

Kelyniam Global Renews Licensing Agreement with Finceramica

Kelyniam Global Renews Licensing Agreement With Finceramica, Unlocking Access to Valuable Pipeline Products

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/KLYG"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"KLYG","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KLYG\",,,,,undefined,":{"symbol":"KLYG","market":"US","secType":"STK","nameCN":"Kelyniam Global, Inc.","latestPrice":0.1398,"timestamp":1770750720000,"preClose":0.1398,"halted":0,"volume":0,"delay":15,"changeRate":0,"floatShares":49410800,"shares":50543400,"eps":-0.007359,"marketStatus":"Trading","change":0,"latestTime":"02-10 14:12:00 EST Delay","open":0.1398,"high":0.1398,"low":0.1398,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-0.007359,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1770757200000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"PINK","adjPreClose":0.1398,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KLYG\",,,,,undefined,":{"symbol":"KLYG","floatShares":49410800,"roa":"-9.25%","roe":"-31.64%","lyrEps":-0.007359,"shares":50543400,"dividePrice":0,"high":0.1398,"amplitude":0,"preClose":0.1398,"low":0.1398,"week52Low":0.053,"pbRate":"11.40","psRate":"2.64","week52High":0.3399,"institutionHeld":0,"latestPrice":0.1398,"eps":-0.007359,"divideRate":0,"volume":0,"delay":15,"ttmEps":-0.007359,"open":0.1398,"prevYearClose":0.1165,"prevWeekClose":0.1225,"prevMonthClose":0.13,"prevQuarterClose":0.1165,"fiveDayClose":0.13,"twentyDayClose":0.117,"sixtyDayClose":0.155},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/KLYG\",params:#limit:5,,,undefined,":[{"market":"US","date":"2021-05-18","symbol":"KLYG","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1621310400000,"reportTimeType":"pre","actualEps":null},{"market":"US","date":"2021-04-02","symbol":"KLYG","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1617336000000,"reportTimeType":"pre","actualEps":null},{"market":"US","date":"2020-11-16","symbol":"KLYG","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1605502800000,"reportTimeType":"pre","actualEps":null},{"market":"US","date":"2020-05-18","symbol":"KLYG","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1589774400000,"reportTimeType":"pre","actualEps":null},{"market":"US","date":"2019-12-13","symbol":"KLYG","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1576213200000,"reportTimeType":"pre","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"KLYG\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"KLYG\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"KLYG\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2582807634","title":"Kelyniam Global Q3 revenue falls 12% to $2.19 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2582807634","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582807634?lang=en_us&edition=fundamental","pubTime":"2025-11-11 04:56","pubTimestamp":1762808189,"startTime":"0","endTime":"0","summary":"Kelyniam Global Inc. reported year-to-date revenue of $2.2 million for Q3 2025, a decrease of 12.3% compared to $2.5 million in Q3 2024. Gross profit was $1.7 million, down 13.3% from $2.0 million in the prior year period. The company reported an operating loss of $162,400, compared to operating income of $273,200 in Q3 2024. Key business developments included FDA 510 clearance for the Vestakeep resorbable bi-calcium phosphate implant and ongoing Value Analytics review at six major U.S. hospitals, potentially adding over $500,000 in annual recurring revenue. Kelyniam also uplisted to OTCID status on the OTC Markets Group platform.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kelyniam Global Inc. published the original content used to","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nNDL37KqdW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KLYG"],"gpt_icon":0},{"id":"2582076378","title":"Press Release: Kelyniam Global Announces Q3 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2582076378","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582076378?lang=en_us&edition=fundamental","pubTime":"2025-11-11 04:56","pubTimestamp":1762808160,"startTime":"0","endTime":"0","summary":"CANTON, Conn., Nov. 10, 2025 /PRNewswire/ -- Kelyniam Global, Inc. , a leader in custom cranial and craniofacial implants, today reported financial results for the third quarter ended September 30, 2025.-- Year-to-date revenue of $2,186,491, compared to $2,492,607, a decrease of. -- Gross profit of $1,695,496, compared to $1,956,714, a decrease of 13.3%,primarily due to the revenue headwinds offset by stable material costs.reflecting increased investments in sales support and regulatory costs. \"Sales have faced headwinds this year from a slow distributor ramp-up and temporary market share shifts, but through Q3, we're steadily catching up to 2024 levels and building a stronger foundation for sustainable growth,\" said Ross Bjella, CEO of Kelyniam Global. \"The cranial implant sector remains robust, with competitors with overall market projections showing expansion from $1.43 billion in 2024 to over $1.5 billion in 2025. We're capitalizing on this by aggressively adding distributors in un","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4022","R","KLYG","BK4232"],"gpt_icon":0},{"id":"2581704201","title":"Kelyniam Global Renews Licensing Agreement with Finceramica","url":"https://stock-news.laohu8.com/highlight/detail?id=2581704201","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581704201?lang=en_us&edition=fundamental","pubTime":"2025-11-07 08:09","pubTimestamp":1762474186,"startTime":"0","endTime":"0","summary":"Kelyniam Global Inc. has announced the renewal of its licensing agreement with Finceramica Faenza S.p.A., an Italian biomaterials company. The three-year extension grants Kelyniam expanded access to Finceramica's product portfolio, including SINTlife, a fully resorbable synthetic graft, and Surgery V-Connect, a Smart Augmented Reality System. The agreement is expected to strengthen Kelyniam's position in the U.S. market and enable entry into new markets in bone regeneration and orthopedic applications. SINTlife is anticipated to receive FDA clearance within two years.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kelyniam Global Inc. published the original content used to generate this news brief via GlobeNewswire  on November 07, 202","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nNDL184vjF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","LU2210149790.SGD","BK4585","LU2095319765.USD","NDAQ","LU2210150020.SGD","IE00BKPKM429.USD","IE00BGHQF748.EUR","BK4112","BK4588","KLYG","LU0314104364.USD","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2581420490","title":"Kelyniam Global Renews Licensing Agreement With Finceramica, Unlocking Access to Valuable Pipeline Products","url":"https://stock-news.laohu8.com/highlight/detail?id=2581420490","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581420490?lang=en_us&edition=fundamental","pubTime":"2025-11-07 08:09","pubTimestamp":1762474177,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nTUATYWCY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KLYG"],"gpt_icon":0}],"pageSize":4,"totalPage":3,"pageCount":1,"totalSize":9,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/KLYG\",params:#limit:6,delay:false,,,undefined,":[]}}